← Back to Clinical Trials
Recruiting NCT05898269

NCT05898269 Fluid Responsiveness Prediction During Prone Position

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05898269
Status Recruiting
Phase
Sponsor Hospices Civils de Lyon
Condition Acute Respiratory Distress Syndrome
Study Type INTERVENTIONAL
Enrollment 96 participants
Start Date 2023-10-06
Primary Completion 2026-10

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Trendelenburg maneuverEnd-expiratory occlusion test (EE OCC)End-expiratory and end-inspiratory occlusion test (EI OCC)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 96 participants in total. It began in 2023-10-06 with a primary completion date of 2026-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Predicting fluid responsiveness is primordial when caring for patients with circulatory shock as it allows correction of preload-dependent low cardiac output states, while preserving patients of the deleterious effects of excessive fluid resuscitation. Patients with severe acute respiratory distress syndrome (ARDS) treated with prone positioning (PP) are a specific subset of patients, as 1) they frequently present with shock; 2) excessive fluid administration may lead to respiratory worsening due to increased hydrostatic oedema with potential subsequent worse clinical outcome; and 3) all available dynamic tests evaluating fluid responsiveness can only be performed in patients in the supine condition (which in the case of severe ARDS patients in PP occurs only for 8h over 24h). These elements warrant the development of specific tests allowing the clinician to predict fluid responsiveness with enough exactitude when caring for these patients. We hypothesize that there exists diagnostic heterogeneity in the predictive performance of 4 clinical tests to identify fluid responsiveness in ARDS patients in PP. For the matter of this study, these 4 tests are the Trendelenburg maneuver, the end-expiratory occlusion test, the end-expiratory occlusion test associated with the end-inspiratory occlusion test, and the tidal volume challenge. The diagnostic reference of the study will be the relative change in cardiac index measured by transpulmonary thermodilution before and after a 500 ml fluid bolus, and will allow the adjudication of patients as being fluid responsive or not. The primary objective of the study is to determine the area under the ROC curve of each of the 4 tests, with their respective 95% confidence interval. All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus. Patients will only participate once. The expected duration of study participation is 30 minutes maximum.

Eligibility Criteria

Inclusion Criteria: * adult patient (including patient under protective measures/wardship) * with ARDS as defined by the Berlin criteria * in the prone position as per international guidelines * with a calibrated continuous cardiac output monitoring device * with a clinical indication for a fluid bolus as prescribed by the clinician in charge, and fulfilling at least 2 clinical criteria: mottles, tachycardia, hypotension, drop in cardiac output, oliguria, high arterial lactate concentration, or any other detailed criterion * with no respiratory efforts Exclusion Criteria: * acute cor pulmonale * patient treated with veno-venous extra-corporeal membrane oxygenation * hemorrhagic shock * Child-Pugh C cirrhosis * death expected to occur in less than 24h * decision to withhold or suspend active treatments * intracranial hypertension * lower limb amputation * obstruction of the inferior vena cava * acute abdominal syndrome * absence of consent to participate * pregnancy * patient previously enrolled in the same study * lack of affiliation to a social security regimen, as per French legislation * patient deprived of its liberty

Contact & Investigator

Central Contact

Laurent BITKER, Dr

✉ laurent.bitker@chu-lyon.fr

📞 4 26 10 94 93

Principal Investigator

Hodane YONIS, Dr

PRINCIPAL INVESTIGATOR

Hospices Civils de Lyon

Frequently Asked Questions

Who can join the NCT05898269 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Respiratory Distress Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05898269 currently recruiting?

Yes, NCT05898269 is actively recruiting participants. Contact the research team at laurent.bitker@chu-lyon.fr for enrollment information.

Where is the NCT05898269 trial being conducted?

This trial is being conducted at Clermont-Ferrand, France, Lyon, France, Nice, France, Nice, France.

Who is sponsoring the NCT05898269 clinical trial?

NCT05898269 is sponsored by Hospices Civils de Lyon. The principal investigator is Hodane YONIS, Dr at Hospices Civils de Lyon. The trial plans to enroll 96 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology